Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 11/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | PPIA | P62937 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24968426 | 0.89 | MRGPRX4 (0.59) | MRGPRX4NR1H2NR1H3 | |
| SCHEMBL30851256 | 0.89 | MRGPRX4 (0.59) | MRGPRX4NR1H2NR1H3 | |
| SCHEMBL27233839 | 0.77 | RXRA (0.48) | MRGPRX4NR1H2NR1H3 | |
| SCHEMBL30165056 | 0.76 | TIPARP (0.62) | MRGPRX4LMNA | |
| SCHEMBL24968427 | 0.76 | TIPARP (0.62) | MRGPRX4LMNA | |
| SCHEMBL2069334 | 0.75 | LOXL2 (0.68) | MRGPRX4LMNAHPGDLOXL2CYP4F2 | |
| SCHEMBL22469944 | 0.74 | MRGPRX4 (0.78) | MRGPRX4LMNA | |
| SCHEMBL29165959 | 0.74 | MRGPRX4 (0.40) | MRGPRX4NR1H2NR1H3 | |
| SCHEMBL3901919 | 0.74 | MRGPRX4 (0.69) | MRGPRX4LMNAHPGD | |
| SCHEMBL3901040 | 0.74 | MRGPRX4 (0.60) | MRGPRX4LMNAHPGDPPIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) | 2024-10-24 | — | — | US | disclosed |
| EP-4378938-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-06-05 | — | — | EP | disclosed |
| CN-117642393-A | Novel PARP7 inhibitor and application thereof | 上海齐鲁制药研究中心有限公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2023006013-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | PARP6, PARP4, PARP3 | MRGPRX4 1452/4885NR1H2 3795/4885NR1H3 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.